1. Home
  2. GS vs AMGN Comparison

GS vs AMGN Comparison

Compare GS & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Goldman Sachs Group Inc. (The)

GS

Goldman Sachs Group Inc. (The)

N/A

Current Price

$913.87

Market Cap

260.5B

Sector

Finance

ML Signal

N/A

Logo Amgen Inc.

AMGN

Amgen Inc.

N/A

Current Price

$465.66

Market Cap

251.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GS
AMGN
Founded
1869
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
260.5B
251.6B
IPO Year
1998
2002

Fundamental Metrics

Financial Performance
Metric
GS
AMGN
Price
$913.87
$465.66
Analyst Decision
Buy
Hold
Analyst Count
26
34
Target Price
★ $1,030.67
$431.81
AVG Volume (30 Days)
2.0M
★ 2.5M
Earning Date
10-13-2026
11-03-2026
Dividend Yield
★ 2.19%
2.16%
EPS Growth
26.59
★ 88.23
EPS
★ 55.56
14.79
Revenue
N/A
★ $25,424,000,000.00
Revenue This Year
$23.48
$7.41
Revenue Next Year
$1.27
$4.59
P/E Ratio
★ $16.45
$31.64
Revenue Growth
N/A
★ 8.83
52 Week Low
$754.00
$312.39
52 Week High
$1,153.99
$483.99

Technical Indicators

Market Signals
Indicator
GS
AMGN
Relative Strength Index (RSI) 51.49 62.32
Support Level $899.00 $446.45
Resistance Level $945.83 $483.99
Average True Range (ATR) 24.80 11.64
MACD 4.40 -0.65
Stochastic Oscillator 69.97 60.28

Price Performance

Historical Comparison
GS
AMGN

About GS Goldman Sachs Group Inc. (The)

Goldman Sachs is a storied financial institution, founded in 1869 and best known for its role as a leading global investment bank. The firm has a significant reach across global financial centers and has been the leading provider of global merger and acquisition advisory services, by revenue, for the past 20 years. Since the global financial crisis, Goldman has expanded its offerings into more predictable, fee-based businesses like asset and wealth management, which contributed roughly 30% of postprovision revenue at the end of 2025. The firm generates revenue from investment banking, global market making and trading, lending, asset management, wealth management, and a small and declining portfolio of consumer credit card loans.

About AMGN Amgen Inc.

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Share on Social Networks: